Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 5/20 | 0.43 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.43 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.43 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | CALML3 | P27482 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 4/20 | 0.42 |
| ▸ | F10 | P00742 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1176888 | 1.00 | ABCB11 (0.45) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL5707296 | 0.99 | ABCB11 (0.45) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL5707298 | 0.99 | ABCB11 (0.45) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8703285 | 0.90 | MAOA (0.46) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8871678 | 0.90 | MAOA (0.46) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL9028107 | 0.87 | ABCB11 (0.44) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8871159 | 0.85 | F10 (0.52) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8701633 | 0.85 | F10 (0.52) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8489161 | 0.85 | MAOA (0.55) | ABCB11MAOAMAOBCALML3LMNA | |
| SCHEMBL8489164 | 0.85 | MAOA (0.55) | ABCB11MAOAMAOBCALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7892574-B2 | In situ applying oxazolidinone to ear, skins | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2011-02-22 | — | — | US | claimed |
| US-7128928-B2 | Ophthalmic formulation with novel gum composition | PHARMACIA CORPORATION (US) | 2006-10-31 | — | — | US | claimed |
| EP-1471890-B1 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORP (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2006059221-A2 | TOPICAL HYDRO-ALCOHOLIC FORMULATIONS OF OXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-06-08 | — | — | WO | claimed |
| US-6989381-B2 | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading | PHARMACIA CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| EP-1610764-A1 | TASTE-MASKING VEHICLE FOR COATED OXAZOLIDINONE PARTICLES | Pharmacia Corporation (US) | 2006-01-04 | — | — | EP | claimed |
| EP-1311296-B1 | SOLUTION OF AN OXAZOLIDINONE ANTIBIOTIC DRUG | PHARMACIA CORP (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1096934-B1 | OXAZOLIDINONES TO TREAT EYE INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1478404-A1 | OPHTHALMIC ANTIBIOTIC DRUG FORMULATIONS CONTAINING A CYCLODEXTRIN COMPOUND AND CETYL PYRIDINIUM CHLORIDE | Pharmacia Corporation (US) | 2004-11-24 | — | — | EP | claimed |
| EP-1476135-A1 | OPHTHALMIC FORMULATION WITH GUM SYSTEM | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| EP-1311296-A2 | SOLUTION OF AN OXAZOLIDINONE ANTIBIOTIC DRUG | Pharmacia Corporation (US) | 2003-05-21 | — | — | EP | claimed |
| US-6551584-B2 | Oxazolidinone antibacterial drug, for example linezolid, in a concentration effective for treatment or prophylaxis of a grampositive bacterial infection of an eye | PHARMACIA & UPJOHN COMPANY | 2003-04-22 | — | — | US | claimed |
| US-20030027790-A1 | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems | PHARMACIA CORPORATION | 2003-02-06 | — | — | US | claimed |
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| EP-1083900-B1 | USE OF OF OXAZOLIDINONES FOR THE PREPARATION OF A MEDICAMENT FOR TRANSDERMAL DELIVERY | UPJOHN CO (US) | 2002-07-17 | — | — | EP | claimed |
| US-20020068720-A1 | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading | PHARMACIA CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-20020065280-A1 | Oxazolidinones to treat eye infections | COCHRAN ROBERT J (US) | 2002-05-30 | — | — | US | claimed |
| WO-2002030395-A1 | TOPICAL ANTIBIOTIC COMPOSITION FOR TREATMENT OF EYE INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2002015940-A2 | SOLUTION OF AN OXAZOLIDINONE ANTIBIOTIC DRUG | PHARMACIA CORPORATION (US) | 2002-02-28 | — | — | WO | claimed |
| US-20020009483-A1 | TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY | PHARMACIA & UPJOHN COMPANY | 2002-01-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027790-A1 | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems | PDCD2L, TBCD, OXA1L | MAOA 4089/4885MAOB 4340/4885PTGS1 3102/4885 |
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | CUTA, DEK, LPXN | MAOA 1172/4885MAOB 1818/4885PTGS1 2187/4885 |
| US-20020068720-A1 | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading | ABCB11, SLC47A1, TBCD | MAOA 3908/4885MAOB 3598/4885PTGS1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.